# Predictive Study of Serum Endocan for Hemorrhagic Transformation After Reperfusion Therapies in Acute Ischemic Stroke

> **NCT05228080** · — · UNKNOWN · sponsor: **Xijing Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DIAGNOSTIC_TEST:** enzyme-linked immunosorbent assay(ELISA)

## Key facts

- **NCT ID:** NCT05228080
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-01
- **Primary completion:** 2022-11-01
- **Final completion:** 2023-02-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05228080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05228080, "Predictive Study of Serum Endocan for Hemorrhagic Transformation After Reperfusion Therapies in Acute Ischemic Stroke". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05228080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*